Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 3

Status

Unknown 6Recruiting 6Not yet recruiting 3Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 173Leukemia, Myeloid, Acute 153Neoplasm Metastasis 146Breast Neoplasms 143Neoplasms 142Colorectal Neoplasms 135Recurrence 104Ovarian Neoplasms 100Pancreatic Neoplasms 81Lung Neoplasms 81Multiple Myeloma 80Advanced Solid Tumor 80Advanced Solid Tumors 74Prostatic Neoplasms 73Stomach Neoplasms 72Squamous Cell Carcinoma of Head and Neck 72Carcinoma, Hepatocellular 67Glioblastoma 65Melanoma 64Lymphoma, Non-Hodgkin 63Triple Negative Breast Neoplasms 57Myelodysplastic Syndromes 54Lymphoma, B-Cell 53Endometrial Neoplasms 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Glioma 51Lymphoma 49Brain Neoplasms 46Hematologic Neoplasms 44Carcinoma, Renal Cell 44

Interventions

Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Advanced Malignant Tumors × Clear all
NCT07038005 2026-02-09

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 1 Recruiting
96 enrolled

Advanced Malignant Tumors

NCT07016490 2026-01-28

A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 1 Recruiting
15 enrolled

Advanced Malignant Tumors

NCT07043751 2026-01-21

A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Recruiting
216 enrolled

Advanced Malignant Tumors

NCT07032298 2025-07-25

A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 1 Recruiting
30 enrolled

Advanced Malignant Tumors

NCT05868876 2025-03-03

A Phase Ia/Ib Open Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Akeso

Phase 1 Recruiting
205 enrolled

Advanced Malignant Tumors

NCT05877924 2024-03-26

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

NovaRock Biotherapeutics, Ltd

Phase 1 Recruiting
200 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡